跳至主要内容
临床试验/CTRI/2014/02/004410
CTRI/2014/02/004410已完成2 期

A Randomized, Active Controlled, Multicentre, Prospective, Clinical Study to Compare the Efficacy and Safety of Dabur Hepano Tablet with a Marketed Liver Formulation in Liver Disorder Patients with Abnormal Liver Function Test (LFT)

Dabur India Limited0 个研究点目标入组 180 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Willing to provide informed consent to participate in the study
  • Males or females 18-65 years of age.
  • Diagnosis of hepatic disorder with abnormal LFT and clinical icterus
  • Serum total bilirubin level more than equal to 2 mg/dL, AST or ALT >2 times ULN
  • The subject is able and willing to undertake all study-required procedures and has the ability to take oral medications

排除标准

  • Pregnant or lactating mother
  • Suspected hypersensitivity to contents of investigational product liver formulation
  • Known case of hepatitis-B or hepatitis-C
  • Obstructive Jaundice and Advanced liver diseases
  • Subjects with serious illness,
  • Current use of other herbal medicines for liver disorders or recent use within past two weeks
  • Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment or could interfere with his/her participation in, and completion of the protocol

研究者

相似试验